-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, TjIhDWp6usc670Lk7/AAdd7D2mzPAX0Mp7LyjiUhKyyvAUAb+fn/JtLnjMM9XGz0 WZ0cKzzfwpzm10HlqiMzog== 0001193125-08-239378.txt : 20090612 0001193125-08-239378.hdr.sgml : 20090612 20081119171640 ACCESSION NUMBER: 0001193125-08-239378 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20081119 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ALEXION PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000899866 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133648318 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 352 KNOTTER DRIVE CITY: CHESHIRE STATE: CT ZIP: 06511 BUSINESS PHONE: 2037761790 MAIL ADDRESS: STREET 1: 352 KNOTTER DRIVE CITY: CHESHIRE STATE: CT ZIP: 06511 CORRESP 1 filename1.htm SEC RESPONSE LETTER

November 19, 2008

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attn: Jim B. Rosenberg

 

  Re: Alexion Pharmaceuticals, Inc.

Form 10-K for the Year Ended December 31, 2007

Filed February 29, 2008

Form 10-Q for the Quarterly Period Ended September 30, 2008

Filed October 30, 2008

Form DEF 14A

Filed on April 4, 2008

File No. 000-27756

Dear Mr. Rosenberg:

The Company confirms that it is in receipt of a comment letter, the Comment Letter, from the Staff of the Securities and Exchange Commission, dated November 5, 2008, regarding the above-referenced filings of the Company. The Comment Letter requests that the Company respond within 10 business days or tell the Staff when the Company will respond. In order to fully respond to the Comment Letter, the Company believes it will need until December 5, 2008. The Company appreciates the Staff’s willingness to allow for the additional time.

Please call the undersigned at (203) 271-8309 if you have any questions regarding this letter.

Best Regards,

/s/ Vikas Sinha                                

Vikas Sinha

Senior Vice President and Chief Financial Officer

Alexion Pharmaceuticals, Inc.

-----END PRIVACY-ENHANCED MESSAGE-----